VivoSeq
Other

Bruxism

18

Pipeline Programs↗

5

Active Trials↗

6

Companies Involved↗

Bruxism is an emerging landscape with 18 programs across 6 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Merz Pharmaceuticals GmbH, Merz Therapeutics GmbH. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

15/100

Mech. Concentration

67/100

Completion Rate

82/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3M

Merz Pharmaceuticals GmbH

1 program

Phase 3M

Merz Therapeutics GmbH

1 program

Phase 3R

Revance Therapeutics, Inc.

1 program

ApprovedAbbVie logo

AbbVie

1 program

PreclinicalM

Mehmet Turgut

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

22

clinical trials

Completed9 · 41%
Unknown status6 · 27%
Active, not recruiting2 · 9%
Not yet recruiting1 · 5%
Terminated1 · 5%
Recruiting1 · 5%
Other2 · 9%

Clinical Trials

Trial Activity

22 trials

Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism Pain
Recruiting·UUniversity of Baghdad·Phase 4·NCT07109882·60 enrolled
Comparison of Dry Needling and Two Botulinum Toxins for Bruxism
Active, not recruiting·RRecep Tayyip Erdogan University·N/A·NCT07452510·69 enrolled
Effect of Marjoram, Vetiver, and Lavender Oil in the Treatment of Bruxism
Active, not recruiting·NNecmettin Erbakan University·Preclinical·NCT07665398·64 enrolled
A Comparative Study of EMG Biofeedback and Pharmacotherapy for the Treatment of Masticatory Muscle Hyperactivity in Bruxism Patients
Not yet recruiting·—·N/A·NCT06894472·30 enrolled
Selected Disorders and Sleep Bruxism
Enrolling by invitation·WWroclaw Medical University·N/A·NCT03083405·100 enrolled
Which is More Effective in Management of Bruxism: Botox or Occlusal Splints
Completed·OOctober University for Modern Sciences and Arts·N/A·NCT04366869·42 enrolled
Study of the Safety and Efficacy of Botox in Bruxism
Completed·—·Phase 4·NCT00908050·23 enrolled
Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism
Completed·MMashhad University of Medical Sciences·N/A·NCT01255878·20 enrolled
Floral Remedies for Sleep-bruxism Patients
Completed·UUniversidade Federal Fluminense·N/A·NCT03112954·74 enrolled
The Use of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle to Treat Sleep Bruxism
Completed·—·N/A·NCT05620316·22 enrolled
Management of Bruxism in Patients With Implant Overdenture
Completed·—·Phase 1·NCT07361900·48 enrolled
Effectiveness of Botox, Dry Needling, Pharmacological Treatment, and Manual Therapy for Bruxism-Induced Myalgia
Completed·SSaglik Bilimleri Universitesi·N/A·NCT06583551·80 enrolled
Effectiveness of Telerehabilitation-Based Rocabado Exercises Compared With Home-Based Rocabado Exercises in Patients With Myofascial Temporomandibular Dysfunction Accompanied by Bruxism: A Randomised Controlled Trial
Completed·—·Preclinical·NCT07677228·40 enrolled
Influence of Vertical Facial Morphology on Occlusal Force Changes After Masseter Botulinum Toxin Injection in Bruxism: A Prospective T-Scan Study
Completed·BBiruni University·Preclinical·NCT07673471·34 enrolled
Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology
Terminated·—·Phase 3·NCT04722809·1 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)